Close
FINDING CURES TOGETHER<sup>SM</sup>

Stand Up To Cancer Announces SU2C Catalyst™ Collaboration with Genentech to Support New Research on Cancer Treatments and Therapies

11/3/2016

​NEW YORK – Stand Up To Cancer (SU2C) announced today an SU2C Catalyst™ collaboration with Genentech, a member of the Roche Group, that will help accelerate the development of new cancer treatments and combination therapies by giving awardees funding and access to a dozen of the company's medicines.

Genentech will provide funding to support several research projects of $1 to $3 million each over a three-year grant term. Applications will be evaluated by a subcommittee of the SU2C Catalyst Executive Committee.

Proposals for SU2C Catalyst Research Grant: Genentech-Supported Projects must be submitted by noon U.S. ET on Dec. 1, 2016. See the program guidelines. Proposals must be submitted through the proposalCentral website.

SU2C Catalyst is a collaborative program managed by SU2C's Scientific Partner, the American Association for Cancer Research (AACR), that is intended to leverage all facets of the pharmaceutical, biotechnology, diagnostic, and devices industries to bring new treatments to patients as rapidly as possible through early-phase clinical trials or translational research.

The Genentech-supported projects will support research into new uses for 12 approved or  investigational medicines: atezolizumab (Tecentriq®), bevacizumab (Avastin®) (combinations only), alectinib (Alecensa®), cobimetinib (Cotellic®), vemurafenib (Zelboraf®), vismodegib (Erivedge®), trastuzumab (Herceptin®) plus pertuzumab (Perjeta®), obinutuzumab (Gazyva®), emactuzumab, anti-CD40, or idasanutlin. Each of these medicines can be investigated alone or in combination with other compounds, biologics, diagnostics, or devices intended as therapeutic interventions, and/or methods for biomarker identification in the following thematic areas of research: 

  • Role of negative or positive regulatory molecules (biomarkers) as predictors of response to immune therapies in the setting of preoperative versus metastatic clinical settings.

  • Neoantigen identification and predictability of clinical effects of immune therapies (checkpoints, adjuvants, endogenous versus exogenous vaccines).

  • Duration of immune therapies, including after response or disease progression, and impact on immune biomarkers.

"We are deeply grateful for Genentech's support of SU2C Catalyst," said Raymond DuBois, MD, PhD, dean of the College of Medicine, Medical University of South Carolina, and chair of the SU2C Catalyst–Genentech Steering Subcommittee. "The broad range of medicines made available to selected research teams will help pick up the pace at which new treatments are developed for patients who need them."

Collaborations with Merck and Bristol-Myers Squibb through SU2C Catalyst were announced previously.

"We are committed to collaborations like SU2C's Catalyst that can help advance scientific understanding and the development of new treatments to help people with cancer," said Edith Perez, MD, vice president and head of U.S. Medical Affairs for Genentech. "Our goal is to identify which people are most likely to benefit from our medicines as we continue to work towards a cure."

Each SU2C Catalyst project is carried out by a collaborative team of expert investigators. The project must be designed to accelerate the clinical use of therapeutic agents or methods leading to patient involvement within the three-year term of the grant, and to deliver near-term patient benefit, according to the program's guidelines.

Proposals for SU2C Catalyst research projects must be based on perceived opportunities for success, as well as high-priority areas with a critical need for rapid progress beyond current medical care. An emphasis on early-phase, signal-finding clinical trials is encouraged.

SU2C Catalyst is overseen by an executive committee chaired by Nobel Laureate Phillip A. Sharp, PhD, chair of the SU2C Scientific Advisory Committee and institute professor at the Koch Institute for Integrated Cancer Research at the Massachusetts Institute of Technology.

The SU2C Catalyst–Genentech Steering Subcommittee chaired by DuBois will also include three additional academic scientists named by SU2C in consultation with the AACR, and three pharmaceutical industry members named by Genentech. The subcommittee will review submitted grant proposals and make recommendations to the SU2C Catalyst Executive Committee.